GSK plc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? GSK plc trades at $50.54 (market cap $101.13B), while iShares 3 7 Year Treasury Bond ETF trades at $116.41. The key difference: GSK plc pays a 3.61% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and GSK plc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| GSK | IEI | |
|---|---|---|
Market Cap | $101.13B | — |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $120.72 |
52-Week Low | $38.96 | $116.16 |
Enterprise Value | $121.57B | — |
Dividend Yield | 3.61% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid recent dividends, including $0.38 per share in July 2026. News highlights focus on Treasury yield volatility amid inflation data and geopolitical tensions, influencing bond market sentiment.
Outlook is cautious due to bearish technicals and rising yield pressures. Opportunities include government backing and income from dividends, but risks involve Fed rate hike expectations and oil-driven inflation. Investors face volatility from macroeconomic shifts and bond market reactions to policy changes.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →